BACKGROUND: Recent reports suggest genetic polymorphisms influence susceptibility to rituximab-induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. AIMS: We report the largest study to date assessing FCGR3A-V158F polymorphisms in diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/Oncovin (vincristine)/prednisone/rituximab (CHOP-R). The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. METHODS: 115 DLBCL patients treated with CHOP-R were compared with 105 healthy White people controls with regards to FCGR3A-V158F and C1qA-A276G polymorphisms. LON incidence and event-free and overall survival (EFS and OS) were analysed for linkage to either polymorphism. RESULTS: The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A-158V/V genotype was associated with LON compared with V/F (P = 0.028) and F/F genotypes (P = 0.005). Although no patients with either LON or FCGR3A-158V homozygosity relapsed compared with 33% FCGR3A-158F/F and 21% non-LON, this did not translate into improved EFS or OS. CONCLUSIONS: Polymorphic analysis may be a predictive tool to identify those at high risk of LON. Prospective studies are required to establish definitively if LON or FCGR3A-158V/V genotype influences outcome.
BACKGROUND: Recent reports suggest genetic polymorphisms influence susceptibility to rituximab-induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. AIMS: We report the largest study to date assessing FCGR3A-V158F polymorphisms in diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/Oncovin (vincristine)/prednisone/rituximab (CHOP-R). The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. METHODS: 115 DLBCL patients treated with CHOP-R were compared with 105 healthy White people controls with regards to FCGR3A-V158F and C1qA-A276G polymorphisms. LON incidence and event-free and overall survival (EFS and OS) were analysed for linkage to either polymorphism. RESULTS: The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A-158V/V genotype was associated with LON compared with V/F (P = 0.028) and F/F genotypes (P = 0.005). Although no patients with either LON or FCGR3A-158V homozygosity relapsed compared with 33% FCGR3A-158F/F and 21% non-LON, this did not translate into improved EFS or OS. CONCLUSIONS: Polymorphic analysis may be a predictive tool to identify those at high risk of LON. Prospective studies are required to establish definitively if LON or FCGR3A-158V/V genotype influences outcome.
Authors: Juan J Mata-Molanes; Joseba Rebollo-Liceaga; Elena Mª Martínez-Navarro; Ramón González Manzano; Antonio Brugarolas; Manel Juan; Manuel Sureda Journal: Front Oncol Date: 2022-06-24 Impact factor: 5.738
Authors: Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis Journal: Neurotherapeutics Date: 2020-10-14 Impact factor: 7.620
Authors: Hervé Ghesquières; Beth R Larrabee; Corinne Haioun; Brian K Link; Aurélie Verney; Susan L Slager; Nicolas Ketterer; Stephen M Ansell; Richard Delarue; Matthew J Maurer; Olivier Fitoussi; Thomas M Habermann; Fréderic Peyrade; Ahmet Dogan; Thierry J Molina; Anne J Novak; Hervé Tilly; James R Cerhan; Gilles Salles Journal: Hematol Oncol Date: 2016-06-10 Impact factor: 5.271
Authors: Heiner Zimmermann; Theresa Weiland; Jamie P Nourse; Maher K Gandhi; Petra Reinke; Ruth Neuhaus; Mohsen Karbasiyan; Barbara Gärtner; Ioannis Anagnostopoulos; Hanno Riess; Ralf U Trappe; Stephan Oertel Journal: J Immunol Res Date: 2014-02-10 Impact factor: 4.818